The packet lists no genes for this condition, and no inheritance pattern or molecular mechanism is recorded, so the cause is not described in this packet. The disease definition characterizes the condition by its tissue findings, sclerosis and IgG4-positive plasma cell infiltration, which describe the lesions rather than a cause.

The packet does not supply formal diagnostic criteria. According to the disease definition, tissue plasma cells show immunohistochemical staining for IgG4 and serum IgG4 levels are often increased, and increased circulating IgG4 is listed as a frequent phenotype. These are descriptive features and are not presented here as diagnostic criteria.

The packet contains no FDA-approved treatment records and no foundational therapy or GeneReviews management content, so established treatment is not described here. Two orphan drug designations are listed, both for treatment of IgG4-related disease: obexelimab (sponsor Zenas BioPharma) and rilzabrutinib (sponsor Sanofi US Services). An orphan drug designation is not a marketing approval and does not indicate that a drug is available for this condition.

Prognosis is not certified in this packet, and no natural-history information is supplied.

ClinicalTrials.gov records in the packet include active studies for this condition, for example a phase 2 study titled "A Study of Efgartigimod in Patients With IgG4-Related Disease" (NCT07025330, Stanford University, recruiting, estimated completion 2028-06-01) and a phase 2 study titled "A Study of IMM0306 in IgG4-Related Disease" (NCT07621939, ImmuneOnco Biopharmaceuticals, not yet recruiting). Trial titles describe study focus and do not establish outcomes.